Overexpression of mir-183 and mir-494 promotes proliferation and migration in human breast cancer cell lines

Macedo,Taciane; Silva‑Oliveira,Renato  J.; Silva,Viviane  A.O.; Vidal,Daniel  O.; Evangelista,Adriane   F.; Marques,Marcia  M.C.

doi:10.3892/ol.2017.6265

Overexpression of mir-183 and mir-494 promotes proliferation and migration in human breast cancer cell lines

Authors:
- Taciane Macedo
- Renato J. Silva‑Oliveira
- Viviane A.O. Silva
- Daniel O. Vidal
- Adriane F. Evangelista
- Marcia M.C. Marques
View Affiliations

Affiliations: Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, SP 14784‑400, Brazil
Published online on: May 26, 2017 https://doi.org/10.3892/ol.2017.6265
Pages: 1054-1060

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer (BC) is a leading cause of cancer-associated mortality in females worldwide. MicroRNAs (miRNAs or miRs), a type of non‑coding RNA, have been reported to be important in the regulation of BC onset and progression. Several studies have implicated the role of miR‑183 and miR‑494 in different types of cancer. However, the biological functions of these miRNAs in BC remain largely unknown. In the present study, the expression of both miRNAs was assessed in the MDA-MB-231 and MDA‑MB‑468 BC cell lines. It was hypothesized that miR‑183 and miR‑494 serve an important role in regulating the expression of key genes associated with the metastatic phenotype of BC cells. To further understand their role, the expression of these miRNAs was restored in selected BC cell lines. Functional assays revealed that overexpression of miR‑183 or miR‑494 modulated the proliferation and migration of MDA‑MB‑231 and MDA‑MB‑468 cells in vitro. Additionally, retinoblastoma 1 (RB1) was identified to be a downstream target of both miRNAs by in silico analysis. Western blotting revealed that upregulation of miR‑183 was associated with downregulation of RB1 protein in MDA‑MB‑231 cells. In conclusion, the present results support the hypothesis that miR‑183 and miR‑494 serve a pivotal role in BC metastasis, and that miR‑183 may act as an oncogene by targeting RB1 protein in MDA‑MB‑231 cells.

View Figures

View References

1	Munker R and Calin GA: MicroRNA profiling in cancer. Clin Sci (Lond). 121:141–158. 2011. View Article : Google Scholar : PubMed/NCBI
2	Da Sacco L and Masotti A: Recent insights and novel bioinformatics tools to understand the role of microRNAs binding to 5′untranslated region. Int J Mol Sci. 14:480–495. 2012. View Article : Google Scholar : PubMed/NCBI
3	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
4	Meltzer PS: Cancer genomics: Small RNAs with big impacts. Nature. 435:745–746. 2005. View Article : Google Scholar : PubMed/NCBI
5	Gaur A, Jewell DA, Liang Y, Ridzon D, Moore JH, Chen C, Ambros VR and Israel MA: Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res. 67:2456–2468. 2007. View Article : Google Scholar : PubMed/NCBI
6	Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M and Croce CM: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA. 101:pp. 2999–3004. 2004; View Article : Google Scholar : PubMed/NCBI
7	Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, et al: Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 99:pp. 15524–15529. 2002; View Article : Google Scholar : PubMed/NCBI
8	Garzon R, Calin GA and Croce CM: MicroRNAs in cancer. Annu Rev Med. 60:167–179. 2009. View Article : Google Scholar : PubMed/NCBI
9	Chang TC, Wentzel EA, Kent OA, et al: Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell. 26:745–752. 2007. View Article : Google Scholar : PubMed/NCBI
10	Mendell JT: miRiad roles for the miR-17-92 cluster in development and disease. Cell. 133:217–222. 2008. View Article : Google Scholar : PubMed/NCBI
11	Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 103:pp. 2257–2261. 2006; View Article : Google Scholar : PubMed/NCBI
12	Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, et al: MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 65:7065–7070. 2005. View Article : Google Scholar : PubMed/NCBI
13	Galasso M, Sandhu SK and Volinia S: MicroRNA expression signatures in solid malignancies. Cancer J. 18:238–243. 2012. View Article : Google Scholar : PubMed/NCBI
14	Sassen S, Miska EA and Caldas C: MicroRNA: Implications for cancer. Virchows Arch. 452:1–10. 2008. View Article : Google Scholar : PubMed/NCBI
15	Negrini M and Calin GA: Breast cancer metastasis: A microRNA story. Breast Cancer Res. 10:2032008. View Article : Google Scholar : PubMed/NCBI
16	Valastyan S: Roles of microRNAs and other non-coding RNAs in breast cancer metastasis. J Mammary Gland Biol Neoplasia. 17:23–32. 2012. View Article : Google Scholar : PubMed/NCBI
17	Marino AL, Evangelista AF, Macedo T, Silveira HC, Kerr LM, Vieira RA, Longatto AF and Silveira MM: Differential expression profile of microRNAs associated with human breast cancer progression. BMC Proc. 7 Suppl 2:pp. P92013; View Article : Google Scholar
18	Zhao H, Guo M, Zhao G, Ma Q, Ma B, Qiu X and Fan Q: miR-183 inhibits the metastasis of osteosarcoma via downregulation of the expression of Ezrin in F5M2 cells. Int J Mol Med. 30:1013–1020. 2012.PubMed/NCBI
19	Wang J, Wang X, Li Z, Liu H and Teng Y: MicroRNA-183 suppresses retinoblastoma cell growth, invasion and migration by targeting LRP6. FEBS J. 281:1355–1365. 2014. View Article : Google Scholar : PubMed/NCBI
20	He W, Li Y, Chen X, Lu L, Tang B, Wang Z, Pan Y, Cai S, He Y and Ke Z: miR-494 acts as an anti-oncogene in gastric carcinoma by targeting c-myc. J Gastroenterol Hepatol. 29:1427–1434. 2014. View Article : Google Scholar : PubMed/NCBI
21	Silva-Oliveira RJ, Silva VA, Martinho O, Cruvinel-Carloni A, Melendez ME, Rosa MN, De Paula FE, de Souza Viana L, Carvalho AL and Reis RM: Cytotoxicity of allitinib, an irreversible anti-EGFR agent, in a large panel of human cancer-derived cell lines: KRAS mutation status as a predictive biomarker. Cell Oncol (Dordr). 39:253–263. 2016. View Article : Google Scholar : PubMed/NCBI
22	Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29:e452001. View Article : Google Scholar : PubMed/NCBI
23	Kammermann M, Denelavas A, Imbach A, Grether U, Dehmlow H, Apfel CM and Hertel C: Impedance measurement: A new method to detect ligand-biased receptor signaling. Biochem Biophys Res Commun. 412:419–424. 2011. View Article : Google Scholar : PubMed/NCBI
24	Maere S, Heymans K and Kuiper M: BiNGO: A Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks. Bioinformatics. 21:3448–3449. 2005. View Article : Google Scholar : PubMed/NCBI
25	Schneider CA, Rasband WS and Eliceiri KW: NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 9:671–675. 2012. View Article : Google Scholar : PubMed/NCBI
26	Girish V and Vijayalakshmi A: Affordable image analysis using NIH Image/ImageJ. Indian J Cancer. 41:472004.PubMed/NCBI
27	Subik K, Lee JF, Baxter L, Strzepek T, Costello D, Crowley P, Xing L, Hung MC, Bonfiglio T, Hicks DG and Tang P: The expression patterns of ER PR, HER2, CK5/6, EGFR, Ki-67 and AR by immunohistochemical analysis in breast cancer cell lines. Breast Cancer (Auckl). 4:35–41. 2010.PubMed/NCBI
28	Haga CL and Phinney DG: MicroRNAs in the imprinted DLK1-DIO3 region repress the epithelial-to-mesenchymal transition by targeting the TWIST1 protein signaling network. J Biol Chem. 287:42695–42707. 2012. View Article : Google Scholar : PubMed/NCBI
29	Lowery AJ, Miller N, Dwyer RM and Kerin MJ: Dysregulated miR-183 inhibits migration in breast cancer cells. BMC Cancer. 10:5022010. View Article : Google Scholar : PubMed/NCBI
30	Limame R, Wouters A, Pauwels B, Fransen E, Peeters M, Lardon F, De Wever O and Pauwels P: Comparative analysis of dynamic cell viability, migration and invasion assessments by novel real-time technology and classic endpoint assays. PLoS One. 7:e465362012. View Article : Google Scholar : PubMed/NCBI
31	Ohdaira H, Sekiguchi M, Miyata K and Yoshida K: MicroRNA-494 suppresses cell proliferation and induces senescence in A549 lung cancer cells. Cell Prolif. 45:32–38. 2012. View Article : Google Scholar : PubMed/NCBI
32	Holliday DL and Speirs V: Choosing the right cell line for breast cancer research. Breast Cancer Res. 13:2152011. View Article : Google Scholar : PubMed/NCBI
33	Lacroix M and Leclercq G: Relevance of breast cancer cell lines as models for breast tumours: An update. Breast Cancer Res Treat. 83:249–289. 2004. View Article : Google Scholar : PubMed/NCBI
34	Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, et al: A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 10:515–527. 2006. View Article : Google Scholar : PubMed/NCBI
35	Mizuarai S, Machida T, Kobayashi T, Komatani H, Itadani H and Kotani H: Expression ratio of CCND1 to CDKN2A mRNA predicts RB1 status of cultured cancer cell lines and clinical tumor samples. Mol Cancer. 10:312011. View Article : Google Scholar : PubMed/NCBI
36	Chinnam M and Goodrich DW: RB1, development, and cancer. Curr Top Dev Biol. 94:129–169. 2011. View Article : Google Scholar : PubMed/NCBI